Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash from Operations (2016 - 2025)

Organogenesis Holdings has reported Cash from Operations over the past 10 years, most recently at 39420000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 39420000.0 for Q4 2025, up 260.43% from a year ago — trailing twelve months through Dec 2025 was 10309000.0 (down 172.56% YoY), and the annual figure for FY2025 was 10309000.0, down 172.56%.
  • Cash from Operations for Q4 2025 was 39420000.0 at Organogenesis Holdings, up from 3079000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ORGO hit a ceiling of 39420000.0 in Q4 2025 and a floor of 32873000.0 in Q2 2025.
  • Median Cash from Operations over the past 5 years was 8223000.0 (2022), compared with a mean of 6082650.0.
  • Biggest five-year swings in Cash from Operations: soared 287.25% in 2021 and later crashed 793.82% in 2025.
  • Organogenesis Holdings' Cash from Operations stood at 17948000.0 in 2021, then crashed by 56.54% to 7800000.0 in 2022, then surged by 36.08% to 10614000.0 in 2023, then grew by 3.04% to 10937000.0 in 2024, then soared by 260.43% to 39420000.0 in 2025.
  • The last three reported values for Cash from Operations were 39420000.0 (Q4 2025), 3079000.0 (Q3 2025), and 32873000.0 (Q2 2025) per Business Quant data.